COVID-19: India to produce over 100 million doses of Russia’s Sputnik V vaccine​​​​​​​

Russia's sovereign wealth fund (RDF) on vember 26 anunced that it will produce more than 100 million doses of COVID-19 vaccine Sputnik V annually in India starting 2021 in collaboration with Hetero Biopharma, one of India’s leing generic pharmaceutical companies. In an official statement, Moscow's sovereign wealth fund said that Gamaleya Center and RDIF have achieved positive results during second interim data analysis of largest double-blind, randomized, placebo-controlled Phase III clinical trials of world’s first registered coronavirus vaccine. Having confirmed high efficacy of its experimental candidate, Russia will begin manufacture and distribution as Moscow has received a request for 1.2 billion doses of Sputnik V from more than 50 countries. 

“We are delighted to anunce agreement between RDIF and Hetero that will pave way to production of safe and highly effective Sputnik V vaccine on Indian soil,” Kirill Dmitriev, CEO of Russian Direct Investment Fund said.

CEO of Russian Direct Investment Fund said, “ vaccine’s interim clinical trial results show 95% efficacy on 42nd day after first dose,” ding that he is “confident that Sputnik V should become an integral part of national vaccine portfolio of every country willing to protect its population from coronavirus.” Furr, Dmitriev lauded India’s cooperation to significantly increase Russia’s vaccine production capacity. he of pharmaceutical firm said that collaboration will help people of India with “an efficient solution in this challenging period of pandemic”. 

Re: 'It's My Right': Brazil President Jair Bolsonaro Will t Take COVID Vaccine

Re: Asian Stocks Mixed Amid Unease About Vaccine Development

‘Make-in-India’ campaign’s objective

International Marketing Director of India’s Hetero Labs Limited, B. Murali Krishna Reddy, appreciated Russia’s choice of India for mass manufacture of COVID-19 vaccines. “We are pleased to collaborate with RDIF as a manufacturing partner for most anticipated Sputnik V vaccine for treatment of Covid-19,” he said. Reddy ded that firm was looking up to clinical trial results in India, saying, “We believe that manufacturing product locally is crucial to enable swift access to patients.”  Calling collaboration “ar step” towards India-Russia's commitment to combat vel coronavirus crisis, Reddy said initiative realized ‘Make-in-India’ campaign’s objective envisioned by Prime Minister of India.

Re: COVID-19: India Says Meeting Nepal’s Vaccine Requirement Would Be Priority

Re: PM Modi To Visit Zydus' COVID-19 Vaccine Development Centre In Gujarat